1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. c-Fms


c-FMS (CSF1R, CSF-1R) is located at the cell plasma membrane. c-FMS is the receptor for the ligand colony stimulating factor-1 (CSF1). c-FMS is an integral transmembrane glycoprotein that exhibits ligand-induced tyrosine-specific protein kinase activity, which triggers a signaling cascade eventually affecting transcription of CSF1-responsive genes. c-FMS tyrosine phosphorylation is induced upon binding of CSF1, leading to activation of Ras/Erk and class I-A phosphatidylinositol 3-kinase signaling pathways, which in turn activate the signal transducers and activators of transcription (STATs) pathways, specifically STAT1, STAT3, and STAT5. c-FMS activation by CSF1 results in increased growth, proliferation and differentiation.

c-Fms Related Products (26):

Cat. No. Product Name Effect Purity
  • HY-16749
    Pexidartinib Inhibitor 99.64%
    Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib (PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Anti-tumor activity.
  • HY-12768
    BLZ945 Inhibitor 99.56%
    BLZ945 is a potent, selective and brain-penetrant CSF-1R inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs.
  • HY-10917
    GW2580 Inhibitor 98.45%
    GW2580 is an orally bioavailable and selective inhibitor of c-Fms kinase which completely inhibits human cFMS kinase in vitro at 0.06 μM. GW2580 acts as a competitive inhibitor of ATP binding to the cFMS kinase and inhibits colony-stimulating-factor-1 signaling.
  • HY-101768
    PRN1371 Inhibitor 99.24%
    PRN1371 is a highly selective and potent FGFR1-4 and CSF1R inhibitor with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively.
  • HY-10408
    Ki20227 Inhibitor 99.30%
    Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction.
  • HY-16749A
    Pexidartinib hydrochloride Inhibitor 99.95%
    Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Anti-cancer activity.
  • HY-114153
    PLX5622 Inhibitor
    PLX5622 is a highly selective brain penetrant and oral active CSF1R inhibitor, for extended and specific microglial elimination, preceding and during pathology development. PLX5622 demonstrates desirable PK properties in varies animals.
  • HY-126297
    c-Fms-IN-10 Inhibitor
    c-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, an kinase inhibitor of FMS (Colony stimulating factor-1 receptor, CSF-1R) with IC50 of 2 nM. c-Fms-IN-10 has anti-tumor activity.
  • HY-12009
    Pazopanib Hydrochloride Inhibitor 99.83%
    Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
  • HY-10204
    OSI-930 Inhibitor
    OSI-930 is a potent inhibitor of Kit, KDR and CSF-1R with IC50 of 80 nM, 9 nM and 15 nM, respectively; also potent to Flt-1, c-Raf and Lck and low activity against PDGFRα/β, Flt-3 and Abl.
  • HY-109086
    Edicotinib Inhibitor 99.88%
    Edicotinib is a selective and orally available colony-stimulating factor-1 (CSF-1) receptor inhibitor, and has entered phase IIA clinical trial to study rheumatoid arthritis (RA) despite disease.
  • HY-18787
    c-Fms-IN-2 Inhibitor 99.05%
    c-Fms-IN-2 is a FMS kinase inhibitor with an IC50 of 0.024 μM.
  • HY-13838
    PLX647 Inhibitor 98.20%
    PLX647 is a highly specific dual FMS/KIT kinase inhibitor with IC50 of 28/16 nM respectively.
  • HY-117244
    AZD7507 Inhibitor 99.45%
    AZD7507 is a potent and orally active CSF-1R inhibitor, with antitumor activity.
  • HY-111787
    CSF1R-IN-2 Inhibitor 99.97%
    CSF1R-IN-2 (compound 5) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.
  • HY-122906
    JTE-952 Inhibitor
    JTE-952 is a potent, oral active and selective Type II inhibitor of colony stimulating factor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC50 values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse collagen-induced model of arthritis.
  • HY-101526R
    GENZ-882706(Raceme) Inhibitor 98.79%
    GENZ-882706(Raceme) is the racemate of GENZ-882706.
  • HY-13075
    c-Fms-IN-3 Inhibitor 99.39%
    c-Fms-IN-3 is a novel c-Fms kinase inhibitor with a potential as anti-inflammatory agent and antirheumatic agent.
  • HY-101526
    GENZ-882706 Inhibitor
    GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1.
  • HY-119942
    c-Fms-IN-8 Inhibitor
    c-Fms-IN-8 (compound 4a) is a colony stimulating factor-1 receptor (CSF-1R, c-FMS) Type II inhibitor, with an IC50 of 9.1 nM.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.